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2 Abbreviations 
 
ADH   Atypical ductal hyperplasia 
CD   Cluster of differentiation 
CGH   Comparative genomic hybridisation 
CNB   Core needle biopsy  
ConA   Concanavalin A 
CV   Coefficient of variation 
DBA   Dolichos biflorus agglutinin 
DC   Ductal carcinoma 
DCIS   Ductal carcinoma in situ 
DI   DNA index 
EGFR   Epidermal growth factor receptor 
ER   Oestrogen receptor 
FISH   Fluorecence in situ hybridisation 
FITC   Fluorescein isothiocyanate 
FNA and FNAB Fine needle aspiration biopsy 
HPA   Helix pomatia agglutinin  
IHC   Immunohistochemistry 
LC   Lobular carcinoma 
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LCIS   Lobular carcinoma in situ 
LOH   Loss of heterozygosity 
mAb   Monoclonal antibody 
NPI   Nottingham prognostic index 
PNA   Peanut agglutinin 
PR   Progesteron receptor 
RCA   Ricinus communis agglutinin 
SLN   Sentinel lymph node biopsy 
SPF   Synthesis phase fraction 
UEAI   Ulex europaeus agglutinin 
WGA   Wheat germ agglutinin 
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3 Introduction 
 
Breast cancer is the most frequent malignancy of Finnish women leading to death 
(Registry 1996). Once locally excised, some breast cancers are cured, while others 
progress rapidly or leading to death even after staying dormant for many years. 
This difference in the behaviour of the tumours can not be foreseen by 
morphological criteria alone (Silvestrini et al. 1995). Reliable prediction of the 
course of the disease has thus far not been possible, despite constant attempts 
(McGuire and Clark 1992; Moss et al. 1994). With the advent of new investigative 
methods based on molecular biology, the cancer cells can be more accurately 
characterised, and perhaps targeted by new specific therapeutic agents (Neville et 
al. 1992; Silvestrini et al. 1993; Silvestrini et al. 1994).  
 
Cancer treatment has become more effective, but also more expensive. Besides 
different kinds of surgical procedures, oncologists now use hormones and 
antihormones (Harris et al. 1992), radiotherapy (Lavin et al. 1994; Meyn et al. 
1996), many kinds of chemotherapy (Neville et al. 1992), and immunotherapy 
(Voelker 2000). Profound knowledge of the specific properties of tumours 
provides an opportunity to tailor individual cancer treatment for each patient 
(Neville et al. 1992). 
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With the emergence of screening for breast cancer also premalignant diseases are 
found (Murphy et al. 1995). Their malignant potential is variable, and the follow-
up of these patients may be problematic (Kerlikowske et al. 1995). Knowledge of 
the recurrence risk in different diseases may save the patient undue anxiety and the 
community unnecessary costs. 
The established markers for a favourable prognosis in breast cancer are the 
absence of lymph node metastasis (Toikkanen and Joensuu 1990), small tumour 
size (Toikkanen and Joensuu 1990), and low histological grade (Blamey et al. 
1979; Bloom and Richardson 1957; Toikkanen and Joensuu 1990). Some selected 
histological types of breast cancer, such as mucinous carcinoma, have also been 
found to behave in a more benign fashion than other types of cancer (Toikkanen 
and Kujari 1989). 
This study attempted to identify further characteristics of breast tumours useful for 
the oncologists in their selection of treatment methods. The means were: Lectin 
staining and flow cytometric analyses of advanced breast cancer, both primary 
tumours and their metastases. Flow cytometry was done from fine needle 
aspiration biopsies (FNAB) and tissue samples of malignant tumours, and the 
accuracy of these different diagnostic methods was compared. Finally, 
immunohistochemistry (IHC) of small,unpalpable breast cancers and known 
premalignant lesions was done with a panel of seven antibodies related to cell 
proliferation and cell death. 
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4 Review of the literature 
4.1 Breast cancer incidence in Finland 
 
The incidence of breast cancer in Finland has grown steadily during the 1980s, and 
outnumbered the incidence of cancer of the digestive tract in the beginning of the 
‘90s (Registry 1996). Although the cumulative five-year survival rate with modern 
therapy (1985-1989 in Finland) was 79% (Registry 1996), this disease leads to 
about 1870 deaths annually (1997). Of these women, 24% are still below 50 years 
of age at the time of diagnosis (Registry 1996) making the loss for the society 
even greater. Finding means for at least extending their survival is worthwhile.  
4.2 Screening for breast cancer 
 
One of the most important prognostic markers is tumour size (Joensuu and 
Toikkanen 1991; Rosen et al. 1992). Detection of the cancer at an early stage is 
therefore believed to be essential. This is the philosophy behind the national breast 
cancer screening programmes instituted in many Western countries. Efficient 
screening has been claimed to reduce breast cancer mortality (Antman and Shea 
1999; Kerlikowske et al. 1995; Miller et al. 2000; Nyström et al. 1993; Senie et al. 
1994). Critics, however, have claimed that screening finds the wrong cancers, i.e. 
those that would not be fatal anyway (Groenendijk et al. 2000; Kallioniemi et al. 
1989; Klemi et al. 1992). The screening of large populations is associated with 
socio-economic side effects, e.g. anxiety in the screened population . We therefore 
have to know what we are looking for, and how to deal with the findings.  
So far, the only method to find breast cancer when the tumour is smaller than 1cm 
in diameter, and still not palpable, is mammography (Antman and Shea 1999). 
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Mammography is not an absolute tool, however. It may fail when the breast tissue 
is very fibrotic (Lam et al. 2000; Mandelson et al. 2000), as it often is in young 
women, and in those receiving hormonal replacement therapy (Lam et al. 2000). It 
also fails if done too infrequently. Also, some types of tumours are difficult to see 
on the mammograms (Porter et al. 2000; Silverstein et al. 1994). Young women 
have to have screening mammograms taken at shorter intervals in order for the 
screening to be effective. This has a negative psychological effect on the healthy 
women targeted, and is one reason why some countries have not started screening 
programmes for breast cancer (Cockburn et al. 1994). The death rate due to breast 
cancer in such countries is nevertheless increasing (Antman and Shea 1999), while 
it is not in countries with an effective screening programme (Nyström et al. 1993). 
One conclusion to be drawn from the recent data is, that participation in screening 
programmes is a favourable prognostic factor (Antman and Shea 1999). 
The Canadian National Breast screening study has, however, shown that annual 
screening with skilled physical examination alone, with the teaching of breast self-
examination is as effective as mammography in reducing breast cancer deaths 
(Miller et al. 2000). This result is valid regardless of the fact that the tumours and 
their axillary metastases are larger in size at the time of diagnosis than the tumours 
detected by mammography. 
4.3 Diagnosis of breast cancer 
4.3.1 FNA and CNB 
 
When a breast lump or parenchymal change is palpated or seen on a mammogram, 
a tissue sample, either cytological (FNA) (Bondesson and Lindholm 1997; 
Masood 1995; Wilkinson and Hendricks 1993) or histological (CNB) (Gajdos et 
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al. 1999; Sharifi et al. 1999) is taken. The pathologists estimate whether there are 
malignant cells present or whether there is a benign process underlying the 
findings. If only micro-calcifications are seen on a mammogram, histologic 
specimens, CNB or a surgical biopsy, are needed (Tabar 1996). In a study on FNA 
techniques, Kreula concluded that aspiration biopsy can rarely be used on tumours 
smaller than 5 mm in diameter (Kreula 1990).  
The decision of surgical treatment is based on the preoperative findings. When 
radical treatment is decided on, the clinical picture, the mammogram and the 
preoperative cytology/histology must be in concordance with each other. This is 
called a triple diagnosis. When the three are in concordance, it is possible to 
choose between the surgical methods in individual cases (Hermansen et al. 1984; 
Morris et al. 1998; Salami et al. 1999). The concordance is best validated when the 
diagnosticians meet with each other. If there are discrepancies or uncertainties in 
the preoperative diagnostics, intra-operative frozen sections and/or imprint 
cytology of the tumour are recommended before ablation and/or axillary 
evacuation is done (Bianchi et al. 1995; Boerner and Sneige 1998; Ferreiro et al. 
1995). 
4.3.2 Radiography of tissue removed 
 
As surgical treatment aims at radical removal of the cancer (White et al. 1995), the 
tumours are excised with normal tissue around them. To ensure that the diagnosis 
is made from the correct location of the tissue removed, unpalpable, 
mammographically found lesions have to be tagged for the surgeon and the 
pathologist to find them. This is best done by mammography before the operation, 
and again of the removed tissue. The radiologist can also tell whether the tumour 
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has been radically removed by comparing the preoperative mammograms with the 
specimen pictures (Lee and Carter 1995). 
4.3.3 Frozen section  
 
Frozen sections are prepared when a surgeon is uncertain about the nature of a 
tumour, but wants to perform the surgical procedures in one session. The frozen 
sections are done while the patient is still in narcosis. Tissue samples are snap 
frozen, and sectioned in cryostats. Sections of the frozen tissue are rapidly stained, 
and the pathologists have to make immediate decisions about the nature of the 
changes. Small tumours at the margins of radial scars, small infiltrating processes 
in large DCIS processes and very well differentiated tumours may not be reliably 
diagnosed based on frozen sections (Ferreiro et al. 1995; Speights 1994). 
Frozen sections are also used for investigating the margins of large tumours, and 
DCIS changes (White et al. 1995). The surgeon is best able to select the critical 
points of tumour growth to the margins, because fibrous septa between the tumour 
and the central parts of the breast can be palpated when the tissues are cut (Malik 
et al. 1999).  
At centres giving cancer care and where experienced cytological knowledge is 
thus available, frozen sections may be partially substituted by imprint cytology, 
especially for the investigation of resection margins and the evaluation of sentinel 
lymph nodes (Cox et al. 2000) 
4.3.4 Final pathology reports  
 
The final histopathology reports should contain information about all the factors 
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considered to have an impact on patient outcome, e.g. the established prognostic 
markers and an evaluation of the radicality of the operation (Vicini et al. 1999; 
Vicini et al. 2000). The reports are drawn up on the basis of measurements of the 
freshly resected tissue and from formalin-fixed, paraffin-embedded material of the 
operation specimens. Handling of the specimens should be standardised for the 
results to be reliable (Luu et al. 1999; Sauer et al. 1992).  
4.4 Prognosis of breast cancer 
4.4.1 Classical prognostic markers 
4.4.1.1 Stage of the disease 
 
The stage of the disease has been shown to have an impact on patient outcome 
(Palmer et al. 1982). The stage is defined by the pTNM classification which 
includes tumour size, measured from histological sections (pT), extent of axillary 
nodal involvement, number of involved lymph nodes investigated histologically 
(pN), and the extent of distant metastases, verified histologically or cytologically 
(pM) (Hermaneck et al. 1997; Spiessl et al. 1992a). There is ongoing discussion on 
the incorporation of other prognostic factors into the staging system, but so far no 
generally accepted recommendations have been made (Yarbro et al. 1999). The 
prognostic impact of micro-metastases or occult metastases is being debated 
(McGuckin et al. 1996). There is no agreement on the critical size of tumour cell 
clusters that should be regarded as metastases (Cox et al. 2000). 
4.4.1.2 Tumour grade  
 
Already in the 1950s, Scarff, Bloom and Richardson introduced histologic grade 
as a prognostic factor for breast cancer (Bloom and Richardson 1957), and this 
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grading has been validated (Elston 1984; Le Doussal et al. 1989; Toikkanen and 
Joensuu 1990). Tumour grade consists of the ability of cancer cells to form 
glandular structures, their nuclear morphology and mitotic counts (Bloom and 
Richardson 1957). Elston and Ellis have refined and further stressed the 
importance of using histologic grading. They have called their classification 
system, with the inclusion of tumour size and of axillary nodal status, the 
Nottingham Prognostic Index (NPI) (Galea et al. 1992). 
In primary, operable breast cancer, NPI based on tumour size, lymph node 
involvement and histological grade can identify three prognostic groups (PG) with 
10-year survival rates of 83%, 52%, and 13% (Balslev et al. 1994). There are three 
strong predictors of a good prognosis: 1) Small primary tumour size (Arriagada et 
al. 1992; Reiss 1989; Skoog et al. 1987; Toikkanen and Joensuu 1990) . 2) 
Absence of lymph node metastasis (Mann et al. 1999; Rosen et al. 1981; Shek and 
Godolphin 1988; Sunderland and McGuire 1990; Toikkanen and Joensuu 1990)  3) 
Low histological grade (Bloom and Richardson 1957; Pereira et al. 1995; Rank et 
al. 1987; Schumacher et al. 1993; Toikkanen and Joensuu 1990). There are only 
few studies opposing the strong adverse prognostic significance of lymph node 
metastasis (Ciatto et al. 1992; Menard et al. 1994). 
Tumour grade, nuclear morphology (Ciatto et al. 1992; le Doussal et al. 1989) and 
mitotic counts are often considered as separate, independent prognostic markers 
(Aaltomaa et al. 1992a), especially when analysed by morphometric methods 
(Bacus et al. 1999; Wolberg et al. 1999). 
The classical prognostic markers are well established and validated. They form the 
cornerstone of breast cancer diagnostics, and all other prognosis indicators should 
be tested against them. But not even these prognostic markers have proven 
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sufficiently reliable (Arriagada et al. 1992; Sears et al. 1982), and more powerful 
predictors are still searched for (Blamey et al. 1979; Clark 1992b; Clark 1994; 
Clark and McGuire 1983; Clark and McGuire 1989; Davis 1996).  
4.4.1.3 Cancer type 
 
Breast cancer is typed according to its morphology and named after the presumed 
cellular origin in the terminal duct-lobular unit (TDLU) (Azzopardi et al. 1981). 
The type of cancer has been shown to have an impact on survival. Breast cancer is 
largely divided into ductal carcinomas comprising 70-90% of breast cancers; they 
show morphological differention towards ductal epithelium (Elston and Ellis 
1998). Lobular carcinomas, comprising 10-30% of breast cancers, resemble the 
exocrine epithelium in the terminal lobules (Silverstein et al. 1994). 
There are several histological types of ductal carcinoma, including small cell 
ductal and large cell ductal carcinoma (Elston and Ellis 1998; Simpson and Page 
1996). The ductal carcinoma of the small cell variety and lobular carcinoma 
sometimes admix; a special variant of this mixture of low-grade malignancy is 
called tubulo-lobular carcinoma (Elston and Ellis 1998). Small cell ductal 
carcinoma may occur in special subtypes, including tubular, cribriform, mucinous 
(Toikkanen and Kujari 1989) and certain papillary carcinomas. Also large cell 
ductal breast carcinoma grows in several patterns, metaplastic, medullary and 
infiltrating micropapillary carcinoma. An infiltrating ductal carcinoma usually 
provokes the formation of a desmoplasic stroma and scarring, which make such 
carcinomas tumorous and render them discernible in mammography quite early in 
their progression. A ductal carcinoma frequently evokes an inflammatory reaction, 
which is rarely seen in lobular carcinoma (Silverstein et al. 1994). 
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Lobular breast carcinomas are characterised by small cells with a scanty 
cytoplasm. In the cytoplasm there are often perinuclear vacuoles, with small 
periodic-acid-shiff positive dense granules containing glycodelin (Kamarainen et 
al. 1997). The nuclei are pale staining, round, with wrinkling of the nuclear 
membrane (Silverstein et al. 1994). The patients with lobular carcinoma have a 
greater risk of developing cancer in the contra lateral breast than patients with a 
ductal carcinoma (du Toit et al. 1991; Lesser et al. 1982). The majority of bilateral 
cancers are however, of the ductal type (Engin 1994). The lobular carcinomas 
often grow in a diffuse manner, invading most of the breast without forming 
palpable tumours or destroying underlying structures. Due to its growth pattern it 
may also be undetectable mammographically (Silverstein et al. 1994). From the 
pathologist’s viewpoint lobular carcinoma is a great challenge in preoperative 
diagnostics. It may be difficult to identify in FNA due to the small pale nuclei, and 
may not be recognised in CNB and surgical margin specimens during surgery due 
to its diffuse growth pattern. This may explain why lobular carcinomas more 
frequently have local recurrences after breast-conserving therapy (du Toit et al. 
1991). The long-term prognosis of patients with lobular carcinoma is nevertheless 
still better than that of the average breast cancer patient (du Toit et al. 1991). 
4.4.2 Other histological criteria of breast cancer 
4.4.2.1 Vessel invasion and inflammation 
 
Several studies have presented compelling evidence to support the prognostic 
importance of the recognition of tumour cells invading lymphatic and blood 
vessels (Pinder et al. 1994; Toikkanen and Joensuu 1990). This parameter appears 
to be particularly valuable in the hands of experienced histo-pathologists who have 
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developed standardised criteria and expertise in vessel recognition. However, its 
application is seriously hampered by inter-observer and intra-observer differences 
in interpretation. A more uniform and objective approach, such as the use of 
immunohistochemical techniques to recognise endothelial linings, may be helpful 
in overcoming these obstacles. This may render lymphatic and blood vessel 
invasion a reliably reproducible indicator that a pathologist can utilise to recognise 
high-risk patients and recommend appropriate therapy (Lee et al. 1986; Marson et 
al. 1999). 
4.4.2.2 Tumour border 
 
Pushing borders of tumours, instead of ragged infiltrating growth, are also 
considered a sign of poor prognosis (Toikkanen and Joensuu 1990). On the other 
hand, accumulation of lymphocytes at the tumour borders has been regarded a sign 
of good prognosis (Toikkanen and Joensuu 1990). 
 
4.4.2.3 Radial scars 
 
The radial scar concept was born in the eighties (Linell et al. 1986). Radial scars 
are very common. They appear to be remnants of scarring procedures that pull 
tissue inwards, giving the appearance of a star, similar to that of a small ductal 
cancer. At the centre of this still benign scar are elastic bundles that strangle ducts 
and lobules (Linell et al. 1986). At the periphery, there are dilated ducts often with 
different stages of proliferation in the epithelium. There may also be hyperplasia 
and LCIS of the lobules. Linell thought originally that the strangled ductuli in the 
centre were in fact already malignant (Linell et al. 1986). Nowadays radial scars 
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are considered to be normal scars, representing reparative processes that might 
render the tissues more vulnerable to cancerous proliferation (Elston and Ellis 
1998). In mammograms, radial scars appear as “black stars” with an empty centre, 
as opposed to the “white stars” of overt cancers. T he “black stars” have longer 
branches, and they are more slender than the “white stars” in mammograms (Tabar 
1996). 
4.4.2.4 ADH, DCIS and LCIS versus infiltrating cancer 
 
A variety of proliferative lesions in the breasts have been recognised. Most of such 
proliferative changes are associated with a higher incidence of breast cancer than 
normal breast epithelium (Fisher et al. 1999; McDevitt et al. 1992; Raju and 
Vertes 1996). The events that eventually turn such lesions into malignant growth 
are still poorly understood. Patients with ADH have a twofold risk of developing 
an invasive cancer in 5 years as compared to women with normal breast 
epithelium (Dupont and Page 1989; McDevitt et al. 1992). Patients with LCIS and 
with DCIS of the small cell variant have a similarly increased risk of developing 
an infiltrative disease (Fisher et al. 1996; Wärnberg et al. 2000). This risk is 
estimated to be 4-5 times that of average women (Wärnberg et al. 2000). Patients 
with DCIS of the large cell variant will regularly get a cancer at some point in 
their lives. The critical molecular events leading to malignancy are still to be 
identified. Genetic changes, typical of an overt breast cancer, can also be found in 
some of the DCIS and LCIS lesions (Visscher et al. 1996). 
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4.5 Patient-related prognostic markers 
4.5.1 Age of the patient 
 
Age influences the tissues and physiological processes in the body (Clark 1992a). 
Hormone-producing tissues and female reproductive organs are affected in 
particular. Even though the physiological proliferation of epithelia slows down 
with age, the cumulated damage to the genome of epithelial cells increases with 
time. This has an impact on breast cancer in a twofold manner. Although cancer is 
more frequent in postmenopausal patients (Clark 1992a; Dhodapkar et al. 1996), 
the cancers of  premenopausal patients are usually more rapidly progressive 
(Albain et al. 1994; Marcus et al. 1994). Clinical, but not anatomical, tumour size 
is larger in young patients, suggesting higher stromal activity. The policy of 
hormone replacement therapy given to ageing women may increase the risk of 
neoplastic changes in oestrogen-responsive epithelium (Snedeker and Diaugustine 
1996). However, the cancers developing during hormone replacement therapy are 
often of low-grade malignancy (Bonnier et al. 1995b). 
In univariate analyses of breast cancer, the following variables have been found to 
correlate significantly with shortened recurrence-free survival in premenopausal 
women: Young age, large tumour size, high number of metastatic lymph nodes in 
the axilla, high histological grade, and negative ER and PR status of the tumour. In 
multivariate analyses, young age is the most important adverse factor in pre-
menopausal patients, followed by tumour size and histological grade, whereas PR 
status is of borderline significance. All of these variables should be included in 
multivariate analyses testing the value of more recently introduced prognostic 
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factors (Davis 1996; de la Rochefordiere et al. 1993; Dhingra and Hortobagyi 
1996; Mouridsen et al. 1992). Younger women have a higher risk of local 
recurrence but, unlike older women, recurrence of the tumour does not worsen the 
already unfavourable outcome (Bonnier et al. 1995a). 
The effect of age as a prognostic factor in recurrent breast cancer was studied in 
1,168 patients treated according to the Eastern Co-operative Oncology Group 
(ECOG) protocols. Survival was significantly shorter in patients under 35 years of 
age (P = .03). This was true even when other good prognostic factors were present. 
Eighteen prognostic factors were analysed, and their power of predicting survival 
was studied in each of the six age groups. Patients with a better performance 
status, less than three sites of metastases, and without visceral or nodal metastases 
had a longer survival time. A Cox proportional hazards model of survival showed 
that younger age groups, irrespective of menopausal status, had shorter survival 
times. The predicted median survival times after the first recurrence were 491 days 
for patients under 35 years of age, 590 days for patients 36 to 45 years of age, and 
700 days for those over 45 years of age (Falkson et al. 1986). 
 4.5.2 Diet and life-style 
 
In Japan, breast cancer is a rare disease as compared to the Western Countries 
(Tominaga and Kuroishi 1999). When Japanese women emigrate to the USA they 
acquire the same risk for breast cancer as the main population of women in the 
USA in a few generations’ time (Probst-Hensch et al. 2000). This is considered to 
be due to environmental and dietary factors (Maskarinec 2000; Probst-Hensch et 
al. 2000). 
A high body mass index increases the risk for breast cancer (Lam et al. 2000), and 
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is a marker for poor prognosis according to some investigators (Greenberg et al. 
1985), which is, however, denied by others (Obermair et al. 1995).  
Nulliparous women are over-represented among patients with large tumours when 
diagnosed. Women with a late first childbirth have tumours that are more 
disseminated at the time of diagnosis than women with an early first childbirth. 
However, such associations are not seen for women diagnosed with small tumous 
or women with cancer that has not spread widely (Wohlfahrt et al. 1999). 
The same factors that decrease the risk of developing breast cancer have been 
shown to worsen the prognosis of developed breast cancer (Korzeniowski and 
Dyba 1994). An adverse psychological reaction, like depression, related to the 
disease has been reported to be a negative factor for patient outcome (Watson et 
al. 1999). 
4.6 Molecular prognosis markers of breast cancer 
4.6.1 Genetics of breast cancer 
 
Malignant cells are characterised by an unstable genome, making their behaviour 
unpredictable (Gisselsson et al. 2000). Nicolson suggested already in the 
beginning of the eighties that cell surface proteins play a decisive role in the 
process of metastasis (Nicolson 1982). In the classical mouse melanoma 
metastasizing experiments Fidler and Nicholson showed that cells with different 
surface properties had a different propensity for metastasizing into selected organs 
(Fidler 1973). They also found that primary tumours contained subclones of cells 
having different cell surface properties. They thus proposed that this might be at 
least partially caused by post-transcriptional heterogeneity, due to different 
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glycosylation of the same surface molecules. This again might be the result of 
changed expression of the glycosylation enzymes (glycosyl transferases). 
 
4.6.1.1 DNA analysis by flow cytometry 
 
Flow cytometric DNA analysis of breast cancer yields information on the DNA 
content of single cells, i.e. the ploidy and also of the fraction of cells in active 
DNA synthesis, i.e. the proliferative activity (Feichter et al. 1988; Ferno et al. 
1992; Gaglia et al. 1993; Witzig et al. 1994). Knowledge of the DNA synthesis 
phase fraction gives seemingly more important prognostic information than 
knowledge of the ploidy (Beerman et al. 1990; Fallenius et al. 1988; Ferno et al. 
1992; Kallioniemi et al. 1987; Tubiana et al. 1984). Ploidy measured by FC gives 
only crude information on lost or gained genetic material. The prognostic power of 
DNA flow cytometry measurements has been enhanced by combining 
proliferation activity and ploidy (Kallioniemi et al. 1988). 
4.6.1.2 Oncogenes and tumour suppressor genes 
 
Loss of heterozygosity from chromosomes 1, 3p, 4, 6q, 7q, 8p, 11, 13q, 16q, 17, 
18q, and 22q is frequently seen in breast cancer tissues. LOH and chromosomal 
deletions may lead to inactivation or loss of tumour suppressor genes (Bieche et al. 
1999; Knuutila et al. 1999). Proto-oncogenes are normal human genes possessing 
the potential to become oncogenic (Chan and McGee 1987). These genes are 
mostly household genes that are involved in growth, differentiation or survival of 
normal cells. When such genes become overactive, through e.g. DNA damage, 
they may participate in the carcinogenesis (Elledge and Allred 1994). Genetic 
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abnormalities that are frequently observed in breast tumours are amplification of 
the proto-oncogenes (myc and c-neu/erbB-2/her-2). Some protein products of 
tumour suppressor genes in the normal cell arrest the cell cycle, e.g. p53. When 
such a normal protein is absent or inactive, the proliferation of cells can be 
unlimited.  
There have been more or less fruitful attempts to correlate disturbances in 
oncogene functions to the outcome of disease. Reports on the inverse effect of the 
accumulation of HER2 (Lipponen et al. 1993a), bcl-2 (Lipponen et al. 1995), and 
of p53 (Lipponen et al. 1993b) in cells on patient prognosis are numerous. But the 
predictive power of the accumulation of these proteins has not been as strong as 
grade or proliferation.  
In the beginning of nineties, the search for specific genetic lesions in breast cancer 
started anew from studies on hereditary cancers. Several genetic alterations were 
found. Epidemiological studies had revealed a linkage between early-onset breast 
cancer and ovarian cancer. A genetic marker was linked to chromosome 17q21 
(Chamberlain et al. 1993; Eng and Ponder 1993; Friedman et al. 1995). The genes 
involved, BRCA1 and 2, were originally found in Ashkenazi Jewish descendants 
(Goldgar et al. 1993; Goldgar et al. 1994).  
BRCA1 maps proximal to D17S579 on chromosome 17q21 as shown by genetic 
analysis (Chamberlain et al. 1993). Recently it was shown that normal BRCA1 is a 
zink finger protein which binds to introns of important cellular regulatory genes 
(Li et al. 2000). Deletion of the BRCA1 gene in knockout mice is not compatible 
with life (Cressman et al. 1999). In fibroblast cultures, lack of BRCA1 gave rapid 
proliferation, which was further accentuated by a simultaneous lack of p53. Such 
cells were, however, increasingly sensitive to DNA damaging agents, suggesting a 
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role for both gene products in DNA repair functions. After continued culture of 
BRCA1 and p53 deficient cells, cell populations with still increased growth rates 
could be isolated, which could mimic the events that occur during malignant 
transformation in BRCA1 deficient epithelia (Cressman et al. 1999). 
BRCA2 on chromosome 13q12-13, was cloned in 1995 (Goldgar et al. 1995). The 
cells produce maximum levels of BRCA2 mRNA in late G1 and in S-phase. 
Expression of BRCA2 has been shown to be independent of DNA synthesis. The 
kinetics of up-regulation of BRCA2 mRNA appears to be similar to that of 
BRCA1, suggesting that the two genes could be commonly controlled. The results 
also imply that these two tumour suppressor genes are active during the growth of 
normal epithelia, and may guard duplicating DNA (Vaughn et al. 1996a; Vaughn 
et al. 1996b) 
Mutations in BRCA2 are thought to account for as much as 35% of all inherited 
breast cancer [Couch, 1996 #90]. The heterogeneity of the mutations found, 
together with the large size of the gene, make clinical testing for BRCA1 and 
BRCA2 mutations technically challenging (Abeliovich et al. 1997). In sporadic 
breast cancer, LOH of BRCA1 or of BRCA2 does not add decisive prognostic 
value, as stated for familial breast cancer (Bieche et al. 1999). Some investigators 
have doubted the prognostic value of these genetic changes even in familial breast 
cancers (Phillips et al. 1999). 
Certain kinds of breast tumours have certain genetic aberrations. Well 
differentiated ductal carcinomas often show loss of 16q, and a few other genetic 
changes, whereas high grade ductal carcinomas have lots of genetic abnormalities 
(Buerger et al. 1999; Garcia et al. 1999; Gonzalez et al. 1999) , among them, often 
an expression of mutated BRCA2 (Bieche et al. 1999). 
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The gains and losses of genetic material in tumours have lately been extensively 
investigated using CGH and FISH (Kallioniemi et al. 1994; Knuutila et al. 1999; 
Tirkkonen et al. 1998). By DNA and tissue microarrays of tumours, information is 
obtained on more discrete changes in gene structures and/or expression (Barlund 
et al. 1997; Kononen et al. 1998). 
 
4.6.2 Immunohistochemical characterisation of tumours 
 
IHC methods are widely used in diagnostic pathology. The methodology is 
relatively simple, and under stringent conditions fairly reliable (Battifora 1999). 
As most archival material is formalin-fixed and embedded in paraffin, there is 
frequently a need to retrieve antigenic epitopes. The procedure, with antigen 
retrieval and signal enhancement-secondary antibodies, does not allow reliable 
quantitation, but in most instances it is sufficient to show the expression of a 
certain epitope. If quantification is essential, cell line specimens with known 
amounts of the investigated protein may be added to the process for comparison 
(Battifora 1999). The antibodies used must nevertheless be rigorously tested and 
validated, and control slides must be included in every staining procedure 
(Busmanis et al. 1994). Most genetic techniques are more complicated, time-
consuming, and also more prone to errors, and are therefore not as useful in 
clinical pathology as demonstration of gene products by immunohistochemistry 
(Martegani et al. 1999).  
4.6.3 Lectin staining for tumour characterisation  
 
Glycosylation means the modification of cell surface proteins after transcription, 
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thus multiplying the structural diversity of the proteins and also their functions 
(Martegani et al. 1999). Lectins act, as nature’s own antibodies, which recognise 
and bind to specific glycoconjugates. Most lectins are purified from plants. 
Reactivity with some lectins like PNA have been shown to have some predictive 
value by indicating ability for metastasis together with HER2 (Thomas et al. 
1993). Other investigators claim that altered glycosylation has prognostic power in 
itself. Fenlon showed that UEA1 reactivity of the tumour cell was related to the 
disease-free interval and survival, and HPA reactivity was related to lymph node 
stage, time to regional recurrence and to survival in breast cancer patients (Fenlon 
et al. 1987). Paydas has suggested Con A reactivity to correlate with a low tumour 
grade (Paydas et al. 1994). 
 4.6.4 Hormone receptors as markers for differentiation and hormone dependency 
 
Given that the breast is a sex-steroid-dependent organ, the development and 
growth of cancer in the breast is often dependent on sex steroids. The more 
differentiated the cancer is, the more likely it is to depend on these hormones. 
Hormone receptors, oestrogen receptors (ER) and progesterone receptors (PR) 
mediate dependency on oestrogen and progesteron. ER- and PR-negative tumours 
are rarely (<10% probability) dependent on sex hormones for growth (Pascual et 
al. 1983; Reiner et al. 1987; Saez et al. 1984) .  
Measuring the tumour content of ER and PR was first done either by radio-ligand 
binding assay (ER-LBA) or enzyme immunoassay (ER-EIA) (Godolphin et al. 
1981; Gotteland et al. 1994). Nowadays direct IHC demonstration of ER and/or 
PR in tumour cells by mAbs have proven more reliable in predicting prognosis 
and the response to anti-hormone therapy (Chariyalertsak et al. 1999; Cowen et al. 
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1990; Ellis et al. 1985). The presence of PR has turned out to be more reliable than 
the presence of ER as a prognosticator and as an indicator of response to hormone 
therapy (Mathiesen et al. 1991; Merkel and Osborne 1989). Also the impact of 
IHC positivity for ER and PR is combined with other factors affecting patient 
outcome, such as menopausal status and patient age (Mason et al. 1990; Moot et 
al. 1987; Neville et al. 1992; Papatestas et al. 1986) . 
Antibodies against ER were first available in 1985 (Ellis et al. 1985). Initially they 
reacted only with fresh and frozen tissue. MAbs to PR were commercially 
available in 1994, and useful mAbs that react also with formalin-fixed tissue are 
now available (Chariyalertsak et al. 1999; Stierer et al. 1993). Hormone receptors 
are labile proteins that start to degrade immediately after removal of tissue from 
the patient. Prompt fixation or immediate snap freezing of the tissue is therefore 
essential. Extended fixation may also destroy the receptor epitopes (Battifora 
1999). Archival material is therefore not always reliable for immuno-staining of 
hormone receptors. Still, archival material has shown a correlation between 
positive receptor staining of cancers and good prognosis (Stierer et al. 1993). This 
correlation is not independent of tumour grade or other classical prognostic 
markers. ER reactivity shows no independent prognostic value, with the possible 
exception of low grade node-negative, small cancers (Joensuu and Toikkanen 
1992; McGuire et al. 1986). Some investigators have found that ER and PR 
positivity is an independent predictor of good prognosis (Knight et al. 1977; Moot 
et al. 1987). ER- and PR-positive tumours tend to be smaller and of lower grade 
than hormone-receptor-negative tumours (Luna-More et al. 1996). 
Some 40-60% of ER-positive tumours do not respond to hormonal therapy 
(Osborne et al. 1980). This has been considered to reflect the occurrence of 
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alternatively spliced receptor proteins, some of which may be over-active, whereas 
others may have lost their biologic activity. Even normal glandular epithelium in 
the breast contains low amounts of variably spliced receptor proteins (Anandappa 
et al. 2000).  
In 1997 a second ER was cloned and mapped to chromosome 12. This ER was 
named ER beta, and the original ER has been renamed ER alfa. These two ERs 
bear substantial homology with each other (Macgregor and Jordan 1998). In breast 
cancers both ERs are often coexpressed (Jarvinen et al. 2000b).The relative impact 
of the two isotypes of ER on the prognostication and the therapy of breast cancer 
remains to be established. 
 
4.6.5 Kinetics of breast cancer 
4.6.5.1 Proliferation rate 
 
The rate of proliferation has been considered a more powerful prognostic factor 
than tumour size. The estimation of proliferation rate has been done by counting 
the frequencies of mitoses in the histological sections (Aaltomaa et al. 1991), by 
3H-thymidine incorporation tests (Tubiana et al. 1984) or by means of proliferation 
indexes measured by DNA cytometry (Witzig et al. 1994; Witzig et al. 1993).The 
simplest way of measuring proliferation is IHC detection of different proteins 
associated with proliferation. There are several proteins associated with cell 
proliferation. The first antibodies that emerged were the anti-cyclins and 
antibodies against PCNA. The results of immunostaining with these antisera 
correlated with SPF and patient outcome (Aaltomaa et al. 1993; Visscher et al. 
1992). MAbs that react with different epitopes of PCNA, Ki-67 and MIB are now 
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available (Cwikla et al. 1999; Depowski et al. 1999). The expression of 
proliferation-associated antigens during the SPF varies, and so does the number of 
positive cells in the tumours (Thor et al. 1999). The growth fraction plays a key 
role in determining the prognosis of breast cancer patients (Courdi et al. 1989; 
Lorenzato et al. 2000b; Pietilainen et al. 1996). 
4.6.5.2 Apoptosis 
 
Apoptosis is defined as programmed cell death. Apoptosis is energy-consuming, 
and does not give rise to inflammation and scarring. Apoptosis appears as lumpy 
condensation of the chromatin, and apoptotic chromatin particles are engulfed in 
macrophages (Vakkala et al. 1999). 
Several of the genes involved in the regulation of apoptosis are proto-oncogenes or 
tumour suppresser genes. The study of Wang provides evidence that also the 
physiological responses of breast epithelial cells to sex hormones involve control 
of the apoptotic pathway (Wang and Phang 1995). This is also shown for 
antioestrogens like Toremifene (Warri et al. 1993). Deregulation of apoptosis may 
contribute to the pathogenesis of breast cancer, via an imbalance between anti-
apoptotic genes (such as bcl-2/bcl-x) and apoptosis-promoting genes like bax 
(Bargou et al. 1995). Apoptosis and proliferation together define tumour kinetics, 
and both are linked to the prognosis of the patient (de Jong et al. 2000; Nishimura 
et al. 1999; Vakkala et al. 1999). 
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4.6.6 Oncogen products in breast cancer 
4.6.6.1 Fas (CD95), the death receptor 
 
The Fas receptor protein is normally expressed on most epithelial cells. It triggers 
apoptosis when in contact with the Fas-ligand, expressed by activated T-cells. The 
Fas-ligand is a protein homologous with tumour necrosis factor alfa. Down-
regulation of the Fas receptor has been seen in certain drug-resistant breast cancer 
cell lines (Cai et al. 1996). Fas is a cell-surface receptor that exists in two forms, 
transmembrane and soluble. The former induces apoptosis by ligation of FasL or 
agonistic anti-Fas antibody, whereas the latter inhibits Fas-mediated apoptosis by 
neutralising its ligand (Ueno et al. 1999). 
4.6.6.2 p53 
 
The gene for p53 consists of 11 exons encoding for a nuclear phosphoprotein. All 
of the biological function(s) of p53 are still not evident, but substantial data 
indicates that p53 is a transcription factor that regulates cell proliferation and 
apoptosis (Harris 1996). Loss of p53 function eliminates growth arrest in response 
to DNA-damage and facilitates the accumulation of mutations. The main role of 
the p53 gene appears to include control of cell cycle checkpoint(s) and 
maintenance of the integrity of the genome. 
Changes in the p53 gene are the most frequently encountered genomic change in 
human malignancies. Normal p53 protein is rapidly degraded. Most p53 mutations 
result in a non-functional protein that accumulates in tumour cell nuclei, and is 
detectable by IHC (Allred et al. 1993; Lucas et al. 2000). Initial IHC studies of 
p53 in breast cancer focused on the association between cancer prognosis and p53 
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over-expression (Barbareschi 1996). Only about one-third of such studies reported 
an association in the beginning, but differences in techniques and variability in the 
frequency and intensity of immuno-reactivity obscured these early analyses 
(Blazyk et al. 2000).  
Cells lacking normal p53 function have a selective growth advantage and are more 
resistant to ionising radiation and anti-cancer drugs (Aas et al. 1996). Cancers with 
mutated p53 genes may therefore behave more aggressively than tumours with a 
preserved normal function of p53.  
The presence of p53 as detected by IHC has later been reported to predict the 
response to certain apoptosis-inducing cytotoxic drugs (Aas et al. 1996). Despite 
the strong correlation between accumulation of p53 protein and the rate of tumour 
cell proliferation, both factors are independently associated with a poor prognosis. 
This suggests that p53 may have other biological functions in addition to cell-
cycle regulation (Allred et al. 1993). Tissue immuno-reactivity for p53 is 
significantly associated with the tumour grade and a negative ER status (Willsher 
et al. 1996).  
4.6.6.3 HER2 
 
The neu/erbB-2/her-2 oncogene was first discovered by Weinberg and 
collaborators in 1981 (Shih et al. 1981; Shih et al. 1979) in chemically induced rat 
neuroblastomas. The human counterpart was independently cloned using cDNA 
probes from parts of the epidermal growth factor receptor, with which HER2 
shows homology. HER2 is a 185 kDa membrane-bound protein that belongs to the 
tyrosine kinase family (Coussens et al. 1985). The gene is located on human 
chromosome 17q21-22 (Coussens et al. 1985). No ligand to HER2 has been found, 
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but it forms heterodimers with other members of the HER-tyrosinkinase family to 
potentiate the tyrosine kinase activity of, for example, c-erbB-3 and its ligand 
(Graus-Porta et al. 1997).  
HER2 is overexpressed in about 30% of breast cancers (Slamon et al. 1987), 
mainly of the large cell ductal type.  
Expression of HER2 is often more intensive in the DCIS component of cancers, 
suggesting that the protein may play a role in the process of carcinogenesis. But it 
seems that HER2 is no longer needed for the tumour invasion (Allred et al. 1992). 
mAbs against the HER2 protein inhibit the proliferation of cancer cells over-
expressing the receptor (Hudziak et al. 1988). Multivariate analyses using 
proportional hazard regression models have demonstrated that HER2 positivity 
continued to predict a poor outcome even when accounting for the effects of other 
prognostic factors (Anbazhagan et al. 1991). Even when only cases with 
favourable (Stages I and II) nuclear grades were analysed, the overall survival and 
disease-free survival were significantly shorter in HER2-positive cases, with a 9-
fold increase in risk of death and a 3-fold increase in risk of relapse. There is much 
evidence suggesting that the demonstration of HER2 expression by IHC may help 
to define breast cancer patients at greater risk of dying of the disease among 
patients with low-stage/low-nuclear-grade tumours, as such patients have hitherto 
been considered to have a good prognosis (Battifora et al. 1991).  
Amplification of the gene for HER2 has also been shown to be an unfavourable 
marker in inherited breast cancer (Xing et al. 1996). 
Humanised antibodies against HER2 have not quite fulfilled the expectations put 
in them (Piccart 2001; Schaller et al. 1999). But the co-amplification of 
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topoisomerase alfa with the gene for HER2 has changed the first-choice treatment 
modalities of breast cancer (Hellemans et al. 1995; Jarvinen et al. 2000a; Sandri et 
al. 1996)  
4.6.6.4 Bcl-2 
 
An important group of proteins influencing apoptosis is the bcl-2 family of 
proteins, some of which, like Bax (Bargou et al. 1995; Krajewski et al. 1995), 
promote, and others like bcl-2 inhibit apoptosis (Schorr et al. 1999). Bcl-2 is 
normally expressed on the inner mitochondrial membranes in the cell. Bcl-2 
counteracts the pro-apoptotic activity of p53 during tissue growth or repair. The 
bcl-2 gene is located at 18q21 (Nathan et al. 1994). Translocation of the gene 
(t14:18) to an active locus leads to the development of follicular lymphoma 
(Tsujimoto et al. 1985). Via an alternative splicing, this gene can encode two 
proteins of 26 and 22 kDa respectively. The larger protein is more abundant in all 
tissues. A robust expression of bcl-2 protects cells from apoptosis (Lu et al. 1995). 
Other biological functions of bcl-2 protein are not well known, but a role for bcl-2 
in epithelial differentiation towards mesenchyme is suggested (Lu et al. 1995), like 
the participation of bcl-2 in the process of tumorigenesis (Nathan et al. 1994).  
Several studies have shown that a low expression of bcl-2 in breast cancer tissue is 
associated with a poor outcome (Joensuu et al. 1994) and vice versa: High 
expression of bcl-2 is associated with a good outcome for the patient (Lipponen et 
al. 1995; Vakkala et al. 1999). A high level of bcl-2 expression is mostly found in 
well-differentiated tumours and associates with a favourable prognosis. bcl-2 
expression has not, however, proved to be an independent prognostic factor in 
breast cancer (van Slooten et al. 1996), only in node-positive and recurring disease 
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(Vakkala et al. 1999). 
4.6.6.5 p21ras (H-ras) 
 
H-ras genes are rendered oncogenic either by mutation or by overexpression. 
Using a mouse mammary tumour model, consisting of genetically related sister 
sub-lines with variant metastatic capacities, a direct correlation between metastatic 
behaviour and expression levels of normal H-ras was found (Pethe and Shekhar 
1999). Although H-ras mutations are infrequent in breast cancer, occurring only in 
about 5%, there is considerable evidence to suggest that H-ras signalling pathways 
are deregulated in breast cancer cells. Elevated levels of normal H-ras have been 
shown to play a crucial role in tumorigenesis. 50% of human breast cancers 
express elevated levels of H-ras. Thus, it is possible that the aberrant function of 
Ras or Ras-related proteins may contribute to breast cancer development and/or 
progression. Over-expression of the H-ras gene has been postulated to result from 
transcriptional deregulation. Also oestrogen-mediated regulation of H-ras 
transcription takes place in mammary tumour cells (Pethe and Shekhar 1999). 
The precence of H-ras, p21ras oncoprotein was claimed to be as powerful marker 
for poor prognosis as axillary lymph node metastases (Watson et al. 1991). 
Watson found no significant relationship between the levels of p21ras and the 
menopausal status of the patient, tumour ER, grade or clinical stage. There was, 
however, a significant trend for tumours to be associated with lymph node 
involvement when p21ras was increasingly expressed. Elevated levels of p21ras 
were also significantly related to early disease recurrence and death from the 
tumour in early breast cancer (Watson et al. 1991) 
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4.6.7 Adhesion 
 
The invasive and metastatic process is a series of events in which adhesion and 
loss of adhesion are sequentially switched on and off. Loss of adhesion in normal 
epithelial cells leads to cell death, often by apoptosis. Loss or alteration of 
adhesion in malignant cells may lead to metastasis. 
4.6.7.1 CD44 
 
CD44 is a membrane-bound glycoprotein encoded by a gene composed of at least 
20 exons with many alternatively spliced transcripts (Iida and Bourguignon 1995). 
Different splicing variants are expressed on different epithelial cells (Iida and 
Bourguignon 1995; Takeuchi et al. 1995). The gene for CD44 consists of multiple 
domains. The glycosylation of the protein varies according to its surroundings or 
enzymatic balance, rendering it a difficult target for IHC. Especially the variant 
isoforms are frequently not recognised by their specific mAbs due to different 
glycosylation. CD44 is thought to contribute to the interaction between cancer 
cells and the matrix (Martegani et al. 1999). Expression of CD44 by cDNA 
transfection to AU-565 breast cancer cells induced an up-regulated expression of 
the intercellular adhesion molecule 1 (ICAM-1). The induction of ICAM-1 by 
CD44 may affect the morphology, differentiation state, and metastatic propensity 
of mammary tumour cells expressing HER2 (Bacus et al. 1993). 
4.6.7.2 Integrins 
 
The integrins belong to a family of transmembrane receptors that connect the cell 
to the extracellular matrix and anchor it to the cytoskeleton. There are more than 
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20 integrin receptors formed by heterodimerization between different alfa and beta 
subunits. Normal human breast epithelial cells express at least four alfa integrins 
(1,2,3 and 6) and two beta integrins (beta 1 and beta 4) which dimerize to form 
alfa-beta receptors. The integrin bridge is a bi-directional conduit for the transfer 
of information between the surroundings and the cell. Both qualitative and 
quantitative changes in integrin expression have been associated with breast 
cancer (Hansen and Bissell 2000). 
4.6.7.3 Cadherins and catenins 
 
Cadherins form an intercellular zipper between homotypic cells. They are 
transmembrane calcium-binding proteins with varying numbers of conserved 
repeated amino acid sequences (Takeichi 1990).  
E-cadherin (L-CAM, uvomorulin), with a mature protein product of 120 kDa, is 
the epithelial cadherin. The gene for E-cadherin is located on chromosome 16q22 
(Takeichi 1990). It is often lacking in invasive breast cancer cells (Frixen et al. 
1991), especially in lobular cancer (Berx et al. 1995; Rasbridge et al. 1993). There 
are also malignant cells with normal E-cadherin, but with defective catenins 
(Pierceall et al. 1995). Catenins are intracellular proteins that form dimers and 
heteromers between themselves and with cadherins (Nagafuchi et al. 1994).  
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Figure1. E-cadherin-catenin complex. E-cadherin binds to alpha-, 
beta- and gamma-catenin and other linkage proteins and is 
therefore linked to the cytoskeleton. The components of the 
complex bind to each other in a homophilic interaction and play a 
key role in cell-cell adhesion. This interaction is dependent on 
extracellular calcium levels. Catenins bound to E-cadherin may 
exchange with their intracellular pool. 
 
From: JIANG: Br J Surg, Vol 83,437-46 
Figure1. 
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Many aggressive forms of breast cancer express the neural cadherin equivalent N-
cadherin (Nieman et al. 1999). When stimulated with fibroblast growth factor, N-
cadherin-containing cells can produce matrix metalloproteinase-9 with the ability 
to digest components of the extracellular matrix (Hazan et al. 2000). HER2 has 
also been shown to bind to catenins (Ochiai et al. 1994).  
4.6.8 Metastasis 
 
Metastasis is a complicated biological process. It comprises the detachment of 
malignant cells from their original place of growth and their transport to a new 
place of growth. At the new location the tumour cells have to be able to provide 
themselves with nursing blood flow and a suitable matrix environment.  
Metastasis, as a prognostic marker, has been discussed in the context of the stage 
of the disease (Spiessl et al. 1992b). 
Small tumour clusters have been found in the lymph nodes and bone marrow in 
breast cancer patients already when the primary lesion has been only at the DCIS 
stage (Cote et al. 1999). The consequence of this finding for the patient is still 
under debate (Karrison et al. 1999; Spratt 2000), although some investigators have 
shown that the prognosis of those patients with tumour cell clusters in their bone 
marrow aspirates is worse than for those in whom they have not been found (Diel 
et al. 1996; Diel et al. 1992).  
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4.7 Treatment of breast cancer 
 
Surgical removal of the tumour is considered the treatment of choice in breast 
cancer, even though some French radiotherapists have successfully used 
radiotherapy alone (Bataini et al. 1978). This treatment, however, resulted in 
fibrosis of the breast in 10% of the patients (Bataini et al. 1978). Still it appears 
that postoperative radiotherapy adds significant benefit to the prognosis of most 
breast cancer patients (Wallgren et al. 1986). Small tumours at the periphery of the 
mammary gland are preferentially operated on by removal of only one segment of 
the breast (Luu et al. 1999; Malik et al. 1999). Mastectomy is performed when the 
tumours are large, adhere to the skin, or are centrally located. When preservation 
of the breast is very important to the patient, preoperative medication with 
chemotherapy may be given in order to reduce tumour size before the operation. In 
such cases pre-treatment assessment of the known prognostic/predictive markers is 
important, because pre-treated tumours may behave differently than untreated ones 
in the prognostication tests used (Zambelli et al. 1999). 
Evacuation of the lymph nodes from the arm pit is performed routinely today 
when diagnosis of a malignant infiltrative cancer is made. The presence of tumour 
spread to the axillary lymph nodes is the most powerful predictive factor known 
(Jatoi 1999; Zurrida et al. 1999). In 1990 Umberto Veronesi showed that lymph 
node drainage from a certain part of the mammary gland takes place in a certain 
order, first to the sentinel lymph node (Veronesi et al. 1993; Veronesi et al. 1990). 
This enables the staging of breast cancer disease without mutilating the patient 
(Veronesi et al. 1999). The completion of the ongoing evaluation of the sentinel 
lymph node (SNL) studies may alter the policy regarding the axillary evacuation 
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(Cox et al. 2000; McCready et al. 1999). The SLN procedure requires a multi-
disciplinary approach and is a learning process for the whole team (Guenther 
1999). Some investigators also claim that tumours less than 1 cm in diameter have 
such a low risk of lymph node metastasis that their lymph nodes can remain 
uninvestigated altogether (Dimitrakakis et al. 1999).  
The choices of post-operative treatment are made on the basis of established 
prognostic/predictive markers (Winchester 1991). These choices include 
radiotherapy (Lavin et al. 1994), chemotherapy (Sledge et al. 2000; Wood 1994; 
Zambelli et al. 1999), immunotherapy (Schaller et al. 1999; Tokuda et al. 1999) 
and antihormone therapy (Sledge et al. 2000; Teixeira et al. 1995). 
5 Aims of the study 
 
This study was undertaken to identify factors which might predict the behaviour of 
breast cancer, and in particular to find out whether some IHC and/or cell kinetic 
patterns of the cancer cells could predict the outcome to the patient. The specific 
aims of the present study were: 
1. To investigate whether metastatic cells differ from primary tumour cells 
regarding their surface membrane glycoconjugates 
2. To study the prognostic power of ploidy and SPF parameters defined by flow 
cytometry in advanced breast cancer 
3. To determine which of the prognostic factors in our use could be evaluated from 
FNA material  
4. To find out whether preneoplastic epithelium differs from invasive cancer 
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regarding oncogene activation, proliferation and apoptosis-related proteins 
5. To correlate the tumour expression of HER2 and p53 with survival in advanced 
breast cancer. 
6 Materials and methods 
 
Formalin-fixed and paraffin-embedded archival breast cancer material was used in 
all the studies, except the FNAB study (III). Detailed information about the 
numbers and kinds of tissue are given in Table 1 and the original publications (I-
V). For the FNAB study, freshly aspirated tumour cells were examined and 
compared with fresh material from the surgical specimens. 
Table 1: The patient material used in this work. 
Study No. No. of primary tumours No. of metastases 
I 18 21 
II 96 53 
III 52 - 
IV 118 50 
V 97* - 
* of which 35 were benign, 28 in situ carcinoma and 34 malignant 
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6.1 Tumour grading and typing 
 
Tumour typing was performed according to WHO (Azzopardi et al. 1981). The 
pTNM classification was done according to UICC 1992 (Spiessl et al. 1992b). The 
cancers were graded according to Elston and Ellis’ (Elston 1984; Galea et al. 
1992) modification of Bloom and Richardson’s original classification from 1957 
(Bloom and Richardson 1957).  
Benign breast lesions were first classified according to Dupont and Page (Dupont 
and Page 1985) but as there were so few of them in each group, they were pooled 
into atypical ductal hyperplasia (ADH) and papillomas. The ADH group included 
four cases of atypical lobular hyperplasia, one fibroadenoma with unusually 
proliferative epithelium with atypia, and two sclerosing adenomas with an 
unusually florid appearance. Cysts and chronic cystic mastopathia without 
epithelial atypia were excluded. Ductal cancer in situ was graded into 
low/intermediate-grade, and high-grade types, DCIS1-2 and DCIS3. The DCIS1-2 
was further subdivided into those without necrosis (DCIS1) and those with 
necrosis (DCIS2), as described by Silverstein and co-workers (Silverstein et al. 
1995).  
6.2 Lectin histochemistry 
 
FITC-conjugated lectins were used on archival material of primary tumours and 
their metastases. The lectins used and their specificities are given in Table 2 and 
study I. They were all obtained desiccated from Sigma chemicals Co. Ltd. After 
deparaffination and hydration, slides were incubated for 30 min in moist chambers 
in the dark with the FITC-conjugated lectins diluted to 0.05mg/ml in phosphate-
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buffered saline (pH 7.2). The slides were then washed in saline, mounted in 
veronal-glycerol, and examined and photographed in a fluorecense microscope. 
 
Table 2: The fluorochrome-conjugated lectins used in this work and their nominal 
specificities.  
 
6.3 Immunohistochemistry (IHC) 
 
IHC was done according to normal laboratory routines with commercially 
available antibodies. In study V antigen retrieval was done by heating in a 
microwave oven. Secondary mAbs were peroxidase-bound, and diaminobenzidine 
was used as substrate. Known positive controls were included in every batch. In 
the FNAB study (III), cells were first sampled into cell culture medium, 
supplemented with albumin and penicillin and streptomycin at 4°C. Within an 
hour, cytocentrifuged preparations were made and stained with toluidine blue for 
immediate diagnosis. When the cells were abundant enough, preparations were 
made for immunohistochemical stainings. The slides were stored at -20°C after 
paraformaldehyde and acetone fixation according to the instructions given by the 
manufacturer of the mAbs . 
Lectin, origin, common name Acronym Carbohydrate specificity Inhibitor
Bandereia simplicifolia, griffonia BSII D-Gal Lactose
Concanavalla ensiformia, jack bean Con A D-GLc, a-D-Man D-GalNac
Helix pomatia, edible snail HPA N-acetyl-galactosamine N-acetyl-galactosamine
Arachis hypogea, peanut PNA Gal-beta-(1-3)-GalNac Lactose
Ricinus communis, castor bean RCA1 Beta-D-Gal Lactose
Ulex europaeus, gorse UEA L-fucose L-fucose
Triticum vulgaris, wheat germ WGA (beta-(1-4)D-GlcNAc)2NeuNAc NeuNAc
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Immunoreactions were done on 4 µm sections of formalin-fixed, paraffin-
embedded tissue according to the manufacturer’s instructions. The antibodies 
used, clone names and suppliers/manufacturers are listed in Table 3. 
The immunoreaction in HER2 staining was considered positive when a brown 
membrane positivity was seen in the cancer cells (Fig.1 B, C, E, F in study V). 
Some tumours with very faint patchy staining were considered negative. In p53 
staining, a brown staining of 10% or more of the nuclei of the cancer cells was 
regarded as positive. The cut-off point was chosen according to current literature 
on p53 (Ciesielski et al. 1995; Davidoff et al. 1991) 
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Table 3: Antibodies used in this work. 
Name of epitope Monoclonal=clone/polyclo
nal 
Source Dilution used/ 
pretreatment 
HER2 (study IV) 3B5 Oncogene Science, Inc, 
Manhasset, NY  
1:10 (10µg/ml) 
pepsin pretreatment 
HER2 (study V) CB11 BioGenex, San Remon, 
CA. Ab no. 134M 
1:50 
microwave 
Bcl-2 124 Daco, Corp. Glostrup, 
Denmark 
1:40 
microwave 
p53 (study IV) PAb 1801 Zymed Lab.Inc. San 
Francisco, CA 
1:20 
microwave 
p53 (study V) DO-7 Daco, Corp. Glostrup, 
Denmark  
1:40 
microwave 
p21ras NCC-RAS-001 Daco, Corp. Glostrup, 
Denmark 
1:40 
No antigen retrieval 
Ki-67 MIB-1 BioGenex, San Remon, 
CA  
1:10 
microwave 
CD 44 DF 1485 Daco, Corp. Glostrup, 
Denmark 
1:20 
microwave 
Fas/APO-1 Rabbit polyclonal Zymed Lab.Inc. San 
Francisco, CA  
1:50 
microwave 
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6.4 Flow cytometry  
 
The flow cytometry in study II was done on a FACS IV cell sorter with a 60 µm 
diameter nozzle and an argon laser for excitation at 488 nm; 200mW total 
emission above 580 nm was measured (Becton-Dickinson FACS Systems, 
Mountainwiew, CA)  
The cell suspensions in study III were analysed with a FACScan flow cytometer 
using the CellFit Cell Cycle analysis software programme for data acquisition and 
analysis (Becton Dickinson Immunocytometry Systems).  
Chicken red cell nuclei were used for calibration of the instrumental settings 
before every measurement. The diploid G0/G1 peak of the cells analysed was at 
two times the channel number of the chicken RBC GO/G1 peak. Freshly prepared 
nuclei of HL-60 cells were analysed by the same channel (200). In both papers 
chicken red blood cells were also added to the specimens as internal controls.  
The DNA-histograms were also analysed manually according to Baisch (Baisch 
and Gerdes 1987). The method with the lowest S-phase was used, and samples 
with background and/or many doublets were gated after collection of the primary 
data. No background subtraction was applied. List mode data were saved on 
diskettes for possible later re-evaluation. DNA indexes (DI) were considered 
diploid when there was only one peak at the same position as the G0/G1 peak of 
the nuclei of the HL-60 cell line and the DI calculated from the external and 
internal standards was 0.9-1.1. These diploid peaks were assigned a DI value of 
1.00. When at least two separate G0/G1 peaks could be identified, the population 
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nearest to the channel of the G0/G1 peak of HL-60 nuclei was considered diploid, 
the DI of the other populations was measured using this peak as a reference.  
The quality of the histograms was estimated by the coefficients of variation (CV) 
of the diploid G0/G1 peak. The manual model estimates the percent CV by 
determining the peak width at the inflection point of the peak, which occurs at 
approximately 60% of the peak height. The CVs of the aneuploid population's 
G0/G1 peaks were used to compare the two methods. The percentage of cells in 
SPF was estimated as the percentage of proliferating cells in the cell population 
with the greatest DI. When theG0/G1 peaks were so close to each other that their 
S-phases overlapped almost completely, a mean value was calculated for both 
populations. 
The FNA material was injected into an ampoule containing sterile RPMI 1461 
(3ml) supplemented with 10% human serum. When there was sufficient material 
in the FNAB, as measured from the firstly stained toluidine blue cytocentrifuged 
preparations, additional cells were pelleted by centrifugation and resuspended in 
50µg/ml of Ethidium bromide (Sigma Chemical Co, cat. no E8751) in 10mM 
TRIS-EDTA buffer (pH 7.4) with 0.3% NP 40 and 1% RNAse (Sigma Chemical 
Co) The sample was then passed through 50 m mesh nylon gauze and analysed by 
a FACSscan4 flowcytometer. 
Surgical specimens were immediately placed on ice, and frozen sections were 
made within 30min. If the tumour was diagnosed as malignant, an adjacent tumour 
section was snap frozen for later mechanical desegregation (mincing with a scalpel 
in cell culture medium on a Petri dish), followed by staining and analysis as 
described above for the FNAs. 
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Flow cytometry from archival material in study II was done on 50 µm thick 
paraffin sections that were deparaffined, rehydrated and lysed with proteinase K. 
The naked nuclei were stained with fluorescein-isothiocyanate as described above. 
 
6.4 Statistical analysis 
 
Statistical analysis comprised the Chi-square test, Fisher's exact test, and Mann-
Whitney rank-sum test, analysis of variance and Student's t-test. If the sample 
distribution was skewed, an appropriate transformation was used before testing. If 
there was a difference in group variance between the results for different 
parameters, as determined by Lewene's test, Welch statistics were used. The life 
table method and Mantel-Cox statistics estimated disease-free time and cumulative 
survival rates. All computations were done using BMDP statistical programs and a 
VAX 8600 computer (Dixon et al. 1983).  
Differences between the groups were determined using Student's paired t-test. 
Regression plots were used to study the correlation between the differences in the 
SPF. Levene's test was also used to determine equality of the variances of the two 
sample acquisition methods. 
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7 Results 
 
7.1 FNA:StudyIII  
 
The first aim of this study was to identify markers useful for preoperative 
prognostication. Fifteen years ago CNBs were not in common use, and FNAB was 
the leading method of preoperative diagnosis. A procedure was developed to make 
cell blocks from FNAB material, allowing IHC to be done on consecutive sections 
from the aspirated material (Krogerus and Andersson 1988). In many laboratories 
it may be easier to make direct smears or multiple cyto-centrifuge preparations 
than cell blocks for IHC, but also in such instances FNAB as well as CNB may be 
used (Railo et al. 1996). 
The quality of flow cytometric histograms was found to be better from FNAB 
material than from tissue samples (III). There were more aneuploid peaks, on 
average, in the FNABs than in the surgical specimens, 33 vs. 23 aneuploid peaks 
out of 63 tumour samples. The correlation between SPA and the frequency of cells 
staining positively for Ki-67 was better in the FNAB material than in the surgical 
specimens.  
The results of flow cytometry from the archival material largely confirmed what 
has been claimed by other investigators. Flow cytometry gave reliable information 
on cell kinetics and ploidy. This information was of prognostic value even in 
advanced breast cancer, but the prognostic power did not exceed that of the stage 
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or grade of the tumour. 
 
7.2 Lectin staining: Study I 
 
The staining pattern as well as staining intensity were recorded. It was concluded 
that there was more variability in the glucoconjugate composition of cells in the 
primary tumour than in the cells of the metastases. Also metastases from the same 
primary tumour could differ in their main lectin reactivity. Both the type and 
intensity of staining apparently changed during the process of metastasis. This 
may reflect clonal selection of the tumour cells to the metastatic site. Staining with 
fluorescent lectins was seen in the cell membrane and cytoplasm or in the nuclei. 
7.3 Proliferative epithelial lesions: Study V 
 
The IHC staining results with seven different mAbs, given in Table 3, in 
proliferative epithelial lesions were variable, and consistency was difficult to 
obtain within the lesions or between the same category of lesions. It was found, 
however, that the more atypical the lesion was, the more the results of the IHC 
staining diverged from the staining patterns of morphologically normal epithelium.  
A lower reactivity for HER2 was seen in ADH than in papillomas, while DCIS 
stained more intensely than invasive cancer. In benign papillomas, the HER2 
positivity associated significantly with a high percentage of staining for CD44.  
The proliferative activity, as measured by MIB1 reactivity, was the highest in 
invasive ductal carcinoma and the lowest in papillomas. There was, however, great 
variability in proliferation activity among ductal carcinomas. A significant 
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difference in MIB1 stainings was seen only between ADH and DCIS3 (p<0.05). 
In normal epithelium, CD44 staining was polarised, seen only in the baso-lateral 
membranes, at the epithelial-myo-epithelial junction. Normal epithelium stained 
more intensely than the malignant lesions, which showed a more haphazard 
distribution of staining for CD44. No significant difference in the total lengths of 
membranes staining positively was observed between the benign, pre-malignant 
and malignant categories of the lesions.  
A positive immuno-staining for Fas was found in about one third of the cells in all 
types of lesions. The lowest intensity of staining was seen in papillomas.  
The mAb for Ras p21 stained cells of both benign and malignant epithelium. The 
p21 staining was difficult to interpret due to extensive background staining. 
DCIS3 and ductal carcinoma of grade III had the lowest frequency of positive 
cells (mean 25±31% (range 0-100) and 25±35% (range 0-100), respectively, and 
lobular carcinoma had the highest percentage (59±34%, range 50-100). 
In staining for bcl-2, the highest percentage of positive cells was seen in 
papillomas and lobular carcinomas (71±33%, range 50-100 and 70±36%, range 
50-100 , respectively) and the lowest in DCIS3 (34±47%, range 0-100). There was 
a tendency towards an inverse correlation between the staining intensities of p53 
and bcl-2 in all groups of lesions. 
In benign papillomas, HER2 positivity was frequently seen in cells staining for 
CD44. 
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7.4 Advanced breast cancer: Study II 
 
It was found that only 44% of the HER2-positive primary cancers and 29% of the 
HER2-negative primary cancers had HER2-positive metastases. This suggests that 
expression of HER2 may associate with metastatic propensity. The histologic 
grade of the primary cancer did not affect the HER2 status of the metastasis. 
Positive staining for HER2 in the primary cancer did not correlate with the ploidy 
or the SPF of the metastasis. HER2-positive metastases were more often (p<0.04) 
aneuploid (DNA index 1.7) than negative (mean DNA index 1.3). The 
proliferation activity was higher in the HER2-positive metastases (mean SPF 
8.7%) than in the HER2-negative metastases (mean SPF of 5.6%), but this 
difference was not significant.  
There was no concordance between HER2-positivity and p53-positivity in this 
material. 
Patients with HER2-positive immunostaining of the primary tumours were free of 
cancer for an average of 1.6 years, and HER2-negative cancer patients, on an 
average of 2.0 years (p=0.8). When survival after recurrence was compared 
between patients with either a HER2-positive or -negative primary cancer, there 
was no significant difference between the two groups. HER2 did not correlate with 
the clinical stage or size of the primary tumour. In histological grade I cancers (23 
patients), 80% of the patients with HER2-positive cancer survived for five years, 
but only 36% of the patients with HER2-negative cancer survived for five years. 
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The difference was, however, not quite significant (p=0.08), study V.  
 
When compared with the primary tumours, it was more common for the 
metastases to lose their positivity for HER2 than to gain it. In four cases a HER2-
negative primary tumour had HER2-positive metastases. One of them was on the 
skin, one in the lung, and two in lymph nodes. The skin metastasis and one of the 
lymph node metastases were lobular cancers; the lung metastasis was a ductal 
cancer of grade II, and the other lymph node metastasis was a ductal cancer of 
grade I (study IV). 
8 Discussion 
 
The prognosis of breast cancer patients has improved during the course of this 
work  (1996-2000) (Registry 1996; Rose'n et al. 2000). It is now apparent that 
most breast cancer patients benefit from adjuvant therapy, regardless of the 
presently used prognostic indexes ((EBCTCG). 1998a; (EBCTCG). 1998b) . 
Patients with a favourable prognosis are nevertheless unnecessarily exposed to 
prolonged medication. Therefore, there is still a demand for better prognostication 
(Knorr et al. 1992; Rosen et al. 1992; Rosner and Lane 1993). The therapy has to 
be tailored individually for each patient, and that is why also predictive measures 
are needed (Klijn et al. 1993; Lavin et al. 1994; Rizzieri et al. 1999; Schaller et al. 
1999). 
Breast cancers are now found and treated at earlier stages, largely due to improved 
mammography equipment (Rose'n et al. 2000). This places demands on the 
diagnostic and therapeutic approaches. The ongoing discussion on the drawbacks 
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and benefits of FNAB contra CNB is one example of this change in attitudes 
(Florentine et al. 1997; Masood 1995; Sharifi et al. 1999; Troncone et al. 1995) . 
Palpable tumours can be easily diagnosed with almost any method. The small 
tumour changes, targeted today by radiographic methods, need careful evaluation 
for the best diagnostic approach. All doctors taking part in the decision making on 
the treatment of breast cancer patients should therefore participate in the 
discussion on the diagnosis, prognosis and treatment of the patients. 
It is important that the community treating breast cancer recognises that it is 
dealing with a disease of changing concepts. The measures taken to combat the 
disease are modulating the behaviour of the disease (studies I and IV) (Zambelli et 
al. 1999). 
Several other investigators have evaluated some of the prognostic markers from 
preoperative cytological specimens. Most of these authors have succeeded in 
finding various cancer-related changes also in preneoplastic diseases (Gillett et al. 
1998; Gupta et al. 1997; Lee 1995; Lucas et al. 2000; Pavelic et al. 1992; 
Siziopikou et al. 1996). Thus, many changes occurring alone in the genome are 
relatively innocent, but selection of a few critical changes probably initiates the 
cancerous transformation (Minami et al. 1998; Moreno et al. 1997; Murphy et al. 
1995). 
Lectin staining has showen that the surface glycoconjugate composition of the 
primary tumours was more heterogeneous than that of their metastases. This has 
been shown also by other investigators by other methods (Gisselsson et al. 2000; 
Könemann et al. 2000), but denied by others (Bonsing et al. 2000). Metastases 
from the same primary tumour to different locations in the body can display 
different patterns of lectin staining, implying that there are many clones in the 
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primary tumour, or that they can aquire different phenotypes in different locations 
(study I). This suggests that the metastatic process may involve a selection for sub-
clones of tumour cells with better survival in a new environment. 
Flow cytometry also showed that primary tumours frequently contained many cell 
lines with different ploidy and proliferation kinetics (studies II and III) (Joensuu et 
al. 1992). With FNAB, it is possible to enrich such populations for investigation, 
as compared to conventional sectioning and suspending the tumour material. Other 
investigators have confirmed this finding (Bach et al. 1991; Lorenzato et al. 
2000a).  
DI was strongly correlated with the grade, and probably therefore was not an 
independent prognosticator in breast cancer patients, as also shown by others 
(Blanco et al. 1990; Stanton et al. 1992; Toikkanen et al. 1989) . Though the SPF 
gives reliable data on proliferation and has prognostic significance (Dressler et al. 
1988; Toikkanen et al. 1989), proliferation can be measured equally reliably with 
IHC (Aaltomaa et al. 1992b; Gaglia et al. 1993). 
Arnelöv and Auer used image cytometry and reported a good and independent 
correlation with DI and prognosis (Arnerlov et al. 1988; Fallenius et al. 1988; 
Feichter 1991; Feichter et al. 1988). Beerman demonstrated improved prognostic 
power of DI by grouping histograms into different prognostic classes (Beerman et 
al. 1990). The concept of histogram type has been successfully used also by others 
(Dieterich et al. 1995; Ferno et al. 1992). As in our studies, Tubiana found an 
agreement on the limitations of ploidy analysis in advanced stages of breast cancer 
(Tubiana et al. 1981). 
The ICH obtained in this study from old archival material must be cautiously 
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interpreted. The fixation conditions of archival material are not always known. 
Variability has been addressed using large series with simultaneous staining, 
including negative and positive controls from the same batch. This makes reading 
of the results more reliable, since it is possible to make background subtraction, 
and subtraction for normal levels of staining (Battifora 1999). 
Expression of HER2, and of many other proteins, may be lost or gained in the 
process of metastasis (study IV). HER2-positive metastases displayed aneuploidy 
more frequently and higher SPF than the HER2-negative metastases. It is possible 
that the HER2-positivity of the primary cancer is not a feature that favours the 
metastatic process; instead, the negative cell clones appeared to metastasise. This 
is in line with the fact that HER2 was less often expressed in the infiltrating than 
in the in situ component of a tumour. HER2 amplification is probably a sign, 
among others, of the tumour-promoting DNA instability. This concept is 
supported by the findings of a higher incidence of aneuploidy in the HER2-
positive tumours and their metastases.  
 
HER2-positivity has been correlated with metastases in axillary lymph nodes and 
with recurrence and visceral metastasis (Kallioniemi et al. 1991). An association 
between the expression of HER2 and the tumour type and tumour diameter as 
reported by Travis and his co-workers, could not be confirmed in this study 
(Travis et al. 1996). This study did not demonstrate that HER2 adds new 
prognostic information to breast cancer patient, as some investigators have shown 
(Lipponen et al. 1993a). There are, however, recent reports on the use of HER2 as 
a predictive marker of sensitivity to therapy (Cance and Liu 1995; Hudziak et al. 
1988) 
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At advanced stages, grade 1, HER2-positive breast cancers are interesting. They 
often lack apparent other criteria for high grade malignancy, such as high SPF, 
aneuploidy, or p53 immunopositivity. However, in our material all of these (four 
cases) had an additional adverse prognostic marker, besides HER2, either in the 
primary tumour or in the metastasis. 
 
Over-expression of HER2 has been studied mainly in primary tumours of the 
breast. Therefore, little information is available on the HER2 status in metastatic 
breast cancer. In the present study, 56% of the HER2-positive primary cancers had 
negative metastases, and, conversely, 29% of the HER2-negative primary cancers 
had positive metastases. This may be due to sampling error, since the study 
included large tumours, and only selected areas of the cancer were studied. 
Therefore HER2-positive clones in the primary HER2-negative cancers could be 
missed. Otherwise the findings suggest that during the process of metastatic 
spread, the cancer cells either lose HER2 over-expression or gain it. 
Ductal cancers were more frequently p53- and CD44-positive and had higher 
proliferative activity than the lobular cancers. The DCISs were more frequently 
positive for p21, bcl-2 and HER2 (study V) than was LCIS. Among the invasive 
cancers, lobular cancers were more often positive for HER2 than were the ductal 
cancers. This might be a reflection of different behaviour in relation to the stroma 
(du Toit et al. 1991). The expression of HER2 showed an inverse correlation with 
the expression of adhesion molecule CD44. Thus, the HER2-positive tumours 
were less positive for CD44 than were the HER2-negative cancers of the same 
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histological type.  
According to my results and those of others (Lucas et al. 2000), aberrant protein 
products are found in premalignant lesions as well as in overt cancers. There was 
only a slight difference in the quantity and the distribution, not the quality of the 
changes. The key difference between invasive and non-invasive tumour cell 
populations remains to be defined. The possibility remains that the difference is 
not inside the cells, but rather outside the cells, in the excreted enzymes and the 
periductular stroma, as suggested by numerous investigators (Foekens et al. 1992; 
Foekens et al. 1994; Foekens et al. 1993; Friedrichs et al. 1995; Frixen and 
Nagamine 1993; Gasparini et al. 1997; Janicke et al. 1993; Joensuu et al. 1995) . 
An interesting molecule is tenascin-C, which appears around micro-invasive cell 
clusters (Jahkola et al. 1998; Jahkola et al. 1996). 
 
The greatest challenge in prognostication, both for pre malignant and overtly 
malignant disease, lies in the heterogeneity of the lesions. Even if the genetic 
aberrations seems to go forward stepwise, the fenotypic diversity in different 
tissues, and even from cell to cell, is endless. It is not the primary tumour, but 
rather the metastatic disease that kills the patient. The ability to metastasise, to 
adhere to vital organs and thrive there, are the key features of a killing disease, as 
stated by Paget already at the end of the nineteenth century (Paget 1889). 
First with the advent of oncogenes, then with more and more detailed 
understanding of cell division and its regulation, I have come to the conclusion 
that understanding cancer is like understanding chaos. It may be possible in 
theory, but not in detail. Instead of taking single parameters as single prognostic 
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factors, we have to think of the tumour as a society, with lots of individuals, and 
the more divergent the population is, the more potential it holds for destroying its 
host. Nicholson, in his discussion on the process of metastasis, concluded that the 
more aggressive metastatic clones had no means of emergin to something new, 
and to send metastases to other locations, as had the heterogeneous primary 
tumour (Nicolson 1982). It may of course be that chance alone decides how a 
cancer cell behaves in its next division, what devious behaviour it will gain, and 
that nothing in the cells predicts a malignant kind of behaviour.  
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9 Summary and conclusions 
Breast cancer is the most significant malignancy of women in Western countries. 
Biologically the disease is heterogeneous and therefore unpredictable. It has 
unique features in its ability of dormancy and early metastasising. These features 
make the disease difficult to cure, and a large number of women live their lives in 
fear of the disease. 
The purpose of this study was to find reasons for this unpredictability. In this 
study, tumour material from advanced disease as well as from early and pre-
malignant disease were investigated with lectin staining, with flow cytometry and 
with IHC for oncogen products and proliferation markers. Primary tumours were 
compared with their metastases, and in situ components of the disease with the 
invasive components. Furthermore, diagnostic procedures, FNAB and histology, 
were compared with each other for diagnostic accuracy. 
The primary tumours were more variable in their staining patterns than their 
corresponding metastases. Single parameters, like SPF, DI, hormone receptors, 
and single oncogene amplifications, did not predict the outcome in advanced 
disease. Deviations from normal epithelium seen in breast cancers were also found 
in pre-malignant disease. Additional markers for cellular changes, and probably 
also for extra-cellular alterations are to be identified, in order to target the crucial 
constellations of malignant behaviour. 
FNAB proved to be better material for flow cytometry than surgically removed 
tissue, and FNAB was also useful for IHC. The investigated parameters gave 
useful information that may help in therapy decisions. 
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